Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.

Authors: Maura L. Gillison, Marc Oliva, Christophe Le Tourneau, Ramy Saleh, Amita Patnaik, Jonathan W. Riess, Neeltje Steeghs, Justin A. Call, Afshin Dowlati, Elisa Fontana, Arjun Oberoi, Nuria Kotecki, Anna Rachel Minchom, Sebastian Ochsenreither, Kaïssa Ouali, Anna Spreafico, Andrea Zivi, Shivani Gupta, Rong Zhang, Lisle Nabell

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.6033

Source: Full article


Abstract

6033